Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 823 participants.

Also called NCT01874431

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 823 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01874431
  • EudraCT 2012-004179-38
Main results
  • Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial JAMA, 2015-09-01 DOI, PubMed 26325557
Other papers using this trial's data
  • Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes Journal of hypertension, 2023-02-01 DOI, PubMed 36583355, PMC9799031 In the PMC Open Access subset under CC BY-NC-ND.
  • Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease Clinical pharmacokinetics, 2020-03 DOI, PubMed 31583611, PMC7051931 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hong Kong SAR China, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01874431. Randomized; quadruple masking; primary purpose treatment. Start 2013-06-12 (actual); primary completion 2014-07-09 (actual). Results posted on 2021-05-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Acronym
ARTS-DN
Condition
Diabetic Nephropathies
Intervention (Drug)
Finerenone (BAY94-8862)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01874431
Content hash
f83b151c3dec387fd2c36c94bcf3caa7e4e8e15089f06969bfad688dbc6e3883